Planned Solutions Inc. Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Planned Solutions Inc. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel reports. The firm purchased 3,426 shares of the company’s stock, valued at approximately $1,997,000. Eli Lilly and Company accounts for 0.9% of Planned Solutions Inc.’s portfolio, making the stock its 17th largest holding.

Other large investors also recently bought and sold shares of the company. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $27,000. Retirement Group LLC boosted its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $33,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $35,000. Finally, Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $778.69 on Thursday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a fifty day moving average of $727.96 and a two-hundred day moving average of $636.01. The company has a market capitalization of $739.88 billion, a price-to-earnings ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the firm earned $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 195,055 shares of company stock worth $125,254,657 over the last quarter. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. Barclays increased their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.